TP53 and cancer: We have previously shown that a panel encompassing p53 immunohistochemistry and TP53 mutation, aurora kinase A (AUKA; a surrogate for aneuploidy), and clinical factors (age and length of Barrett's oesophagus) was able to predict patients with high-grade dysplasia or intramucosal cancer with good accuracy (area under the receiver operating characteristic curve [AUROC] 0·87; 99% CI 0·73–0·95).16